Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 35 of 35 results for bph

  1. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)

    We have moved Medical technologies guidance 58 to become HealthTech guidance 578. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Medical technologies guidance
    Published
    4 May 2021

  2. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)

    We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Medical technologies guidance
    Published
    24 June 2020

  3. Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG629)

    This guidance has been updated and replaced by NICE interventional procedures guidance 770.

    Interventional procedures guidance
    Published
    19 September 2018

  4. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by NICE interventional procedures guidance 737.

    Interventional procedures guidance
    Published
    30 January 2019

  5. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.